• https://doi.org/10.21911/aai.2024.679Copy DOI Icon

Turkish Severe Asthma Program (TSAP)

Show More
  • Abstract
  • Literature Map
  • Similar Papers
Abstract

Severe asthma (SA) is defined as asthma that is uncontrolled under high-dose ICS+LABA treatment or can only be controlled with this high-dose treatment, with a differential diagnosis from difficult asthma.It has been known that severe asthmatics with poor symptom control were reported as 3.7% (range between 3.6-6.1%).Although SA constitutes a very small proportion of all asthmatics, it causes a significant social and psychological burden on patients and on social reimbursement systems.The Turkish Severe Asthma Program (TSAP) was established by stakeholders that include the Turkish National Society of Allergy and Clinical Immunology (TNSACI), representatives from national severe asthma centers, and those from the pharmaceutical industry to develop standards to diagnose and treat patients with SA and to monitor their treatments at the national level.Here we present the TSAP organization and vision.

Similar Papers
  • Research Article

Editorial introductions

  • Feb 01, 2016
  • Current Opinion in Allergy & Clinical Immunology
  • Front Matter

“Where are they now?” Catching up with the 2017 AAAAI Faculty Development Awardees

  • Aug 04, 2022
  • The Journal of Allergy and Clinical Immunology
  • Zuhair K Ballas
  • Research Article
  • Citations21

Advances in pediatric asthma in 2009: Gaining control of childhood asthma

  • Jan 01, 2010
  • Journal of Allergy and Clinical Immunology
  • Stanley J Szefler
  • Research Article

Combined Point-of-Care Assessment Using Oscillometry, Spirometry, and FeNO to Optimally Identify an At-Risk Asthma Phenotype

  • May 01, 2025
  • American Journal of Respiratory and Critical Care Medicine
  • R Chan +14
  • Front Matter
  • Citations65

Expert Panel Report 3: Moving forward to improve asthma care

  • Nov 01, 2007
  • Journal of Allergy and Clinical Immunology
  • William W Busse +1
  • Research Article
  • Citations28

Severe asthma in the US population and eligibility for mAb therapy

  • Dec 19, 2019
  • Journal of Allergy and Clinical Immunology
  • Ayobami Akenroye +2
  • Conference Article

S18 The association of cough-related quality-of-life, cough symptom scores and cough reflex sensitivity with markers of disease control in severe asthma

  • Nov 16, 2018
  • J Holmes +3
  • Research Article

Severe eosinophilic asthma with IgG subclass deficiency treated with benralizumab and IVIG: a case report and literature review

  • Jan 01, 2025
  • Alergologia Polska - Polish Journal of Allergology
  • Mehmet Cakmak +1
  • Research Article
  • Citations21

Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential

  • Oct 20, 2016
  • Therapeutic Advances in Chronic Disease
  • Francesco Menzella +5
  • Research Article
  • Citations37

Modulation of human eosinophil chemotaxis and adhesion by anti-allergic drugs in vitro.

  • Dec 01, 1993
  • Pediatric Allergy and Immunology
  • R Sehmi +6
  • Abstract

P162 The impact of day-case multidisciplinary assessment on asthma control and quality of life scores of patients referred to the manchester severe asthma service

  • Nov 12, 2019
  • Thorax
  • Lj Holmes +4
  • Research Article

Editorial introductions.

  • Aug 01, 2021
  • Current Opinion in Allergy & Clinical Immunology
  • Research Article

Editorial introductions.

  • Oct 01, 2022
  • Current Opinion in Allergy & Clinical Immunology
  • Abstract

298 A comparative study of clinical profile and symptom control in overweight and normal weight school age children with mild persistent asthma

  • Apr 01, 2021
  • BMJ Paediatrics Open
  • Sharmila Manivannan +2
  • PDF
  • Research Article
  • Citations11

Factors influencing poor response to type 2 targeted therapies in severe asthma: a retrospective cohort study

  • Dec 05, 2023
  • BMC Pulmonary Medicine
  • Mona Al-Ahmad +2
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.